Monoclonal Antibodies Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

Description

Persistence Market Research has recently published a detailed report on the global monoclonal antibodies market, providing in-depth insights into key market dynamics, including drivers, trends, opportunities, and challenges. This report presents exclusive data and statistics outlining the anticipated growth trajectory of the monoclonal antibodies market from 2024 to 2031.

Key Insights:

Monoclonal Antibodies Market Size (2024E): US$276.9 Bn
Projected Market Value (2031F): US$729.4 Bn
Global Market Growth Rate (CAGR 2024 to 2031): 12.4%

Monoclonal Antibodies Market - Report Scope:

The monoclonal antibodies market is a critical segment within the biopharmaceutical industry, characterized by the development of engineered antibodies designed to replicate or enhance the immune system's ability to target harmful cells, such as cancer cells. Monoclonal antibodies (mAbs) have become essential in treating various diseases, including cancers, autoimmune disorders, infectious diseases, and chronic conditions. The market's growth is fueled by the increasing global prevalence of chronic diseases and advancements in genetic engineering and biotechnology.

Market Growth Drivers:

The monoclonal antibodies market is propelled by several key factors that are significantly influencing its expansion. Substantial investments in pharmaceutical research and development are driving the creation of new monoclonal antibodies (mAbs) targeting complex diseases such as cancer, autoimmune disorders, and infectious diseases. Pharmaceutical companies are allocating significant resources to enhance the specificity, efficacy, and safety profiles of mAbs, leading to innovations like bispecific antibodies and antibody-drug conjugates that offer more targeted treatment options.

Market Restraints:

Despite promising growth prospects, the monoclonal antibodies market faces challenges, including high production costs, complex manufacturing processes, and stringent regulatory requirements. The need for ongoing research and collaboration among industry stakeholders is critical to overcoming these challenges.

Market Opportunities:

The monoclonal antibodies market presents significant growth opportunities driven by technological advancements and expanding applications in areas like oncology and personalized medicine. The introduction of biosimilars offers cost-effective alternatives, enhancing patient access to essential therapies.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the monoclonal antibodies market globally?
Which advancements in biotechnology are reshaping the competitive landscape of the monoclonal antibodies market?
Who are the key players contributing to the monoclonal antibodies market, and what strategies are they employing to maintain market relevance?
What emerging trends and future prospects are anticipated in the global monoclonal antibodies market?

Competitive Intelligence and Business Strategy:

Leading players in the global monoclonal antibodies market are focusing on innovation, product differentiation, and strategic partnerships to gain a competitive edge. Companies are investing heavily in R&D to develop advanced monoclonal antibody technologies and scalable manufacturing solutions that cater to diverse therapeutic needs.

Key Companies Profiled:

AbbVie Inc.
Amgen Inc.
Genentech, Inc. (Roche)
Johnson & Johnson
Bristol Myers Squibb
Novartis AG
Merck KGaA
GSK plc
Regeneron Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited

Monoclonal Antibodies Market Segmentation

By Source Type

Human
Murine
Chimeric
Humanized

By Production Type

In-vivo
In-vitro

By Application

Infectious Diseases
Neurological Diseases
Autoimmune Diseases
Oncology
Others

By End User

Hospitals
Specialty Centers
Others

By Region

North America
Europe
Asia-Pacific
the Middle East and Africa
Latin America

Product Code: PMRREP34600

1. Executive Summary

1.1. Global Monoclonal Antibodies Market Snapshot, 2024-2031
1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Key Trends
2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
2.4. Forecast Factors - Relevance and Impact
2.5. Covid-19 Impact Assessment

3. Value Added Insights

3.1. Product Adoption / Usage Analysis
3.2. Recent Product Launches and Approvals Insights
3.3. Regulatory Landscape
3.4. Pipeline Analysis
3.5. Promotional Strategies, By Key Players
3.6. Value Chain Analysis
3.7. Porter's Five Force's Analysis
3.8. PESTLE Analysis
3.9. Parent Market Analysis

4. Global Monoclonal Antibodies Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

4.1. Key Highlights
- 4.1.1. Market Size and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
- 4.2.1. Historical Market Size Analysis, 2019-2023
- 4.2.2. Current Market Size Analysis and Forecast, 2024-2031
4.3. Global Monoclonal Antibodies Market Outlook: Source Type
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Mn) Analysis By Source Type, 2019-2023
- 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast By Source Type, 2024-2031
  - 4.3.3.1. Human
  - 4.3.3.2. Murine
  - 4.3.3.3. Chimeric
  - 4.3.3.4. Humanized
4.4. Market Attractiveness Analysis: Source Type
4.5. Global Monoclonal Antibodies Market Outlook: Production Type
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Mn) Analysis By Production Type, 2019-2023
- 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast By Production Type, 2024-2031
  - 4.5.3.1. In Vivo
  - 4.5.3.2. In Vitro
4.6. Market Attractiveness Analysis: Production Type
4.7. Global Monoclonal Antibodies Market Outlook: Application
- 4.7.1. Introduction / Key Findings
- 4.7.2. Historical Market Size (US$ Mn) Analysis By Application, 2019-2023
- 4.7.3. Current Market Size (US$ Mn) Analysis and Forecast By Application, 2024-2031
  - 4.7.3.1. Infectious Diseases
  - 4.7.3.2. Neurological Diseases
  - 4.7.3.3. Autoimmune Diseases
  - 4.7.3.4. Oncology
  - 4.7.3.5. Others
4.8. Market Attractiveness Analysis: Application
4.9. Global Monoclonal Antibodies Market Outlook: End User
- 4.9.1. Introduction / Key Findings
- 4.9.2. Historical Market Size (US$ Mn) Analysis By End User, 2019-2023
- 4.9.3. Current Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2031
  - 4.9.3.1. Hospitals
  - 4.9.3.2. Specialty Centers
  - 4.9.3.3. Academical and Research Institutes
  - 4.9.3.4. Biopharma Companies
  - 4.9.3.5. Others
4.10. Market Attractiveness Analysis: End User

5. Global Monoclonal Antibodies Market Outlook: Region

5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
5.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2031
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. East Asia
- 5.3.4. South Asia and Oceania
- 5.3.5. Latin America
- 5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region

6. North America Monoclonal Antibodies Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis By Market, 2019-2023
- 6.2.1. By Country
- 6.2.2. By Source Type
- 6.2.3. By Production Type
- 6.2.4. By Application
- 6.2.5. By End User
6.3. Current Market Size (US$ Mn) Analysis and Forecast By Country, 2024-2031
- 6.3.1. U.S.
- 6.3.2. Canada
6.4. Current Market Size (US$ Mn) Analysis and Forecast By Source Type, 2024-2031
- 6.4.1. Human
- 6.4.2. Murine
- 6.4.3. Chimeric
- 6.4.4. Humanized
6.5. Current Market Size (US$ Mn) Analysis and Forecast By Production Type, 2024-2031
- 6.5.1. In Vivo
- 6.5.2. In Vitro
6.6. Current Market Size (US$ Mn) Analysis and Forecast By Application, 2024-2031
- 6.6.1. Infectious Diseases
- 6.6.2. Neurological Diseases
- 6.6.3. Autoimmune Diseases
- 6.6.4. Oncology
- 6.6.5. Others
6.7. Current Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2031
- 6.7.1. Hospitals
- 6.7.2. Specialty Centers
- 6.7.3. Academical and Research Institutes
- 6.7.4. Biopharma Companies
- 6.7.5. Others
6.8. Market Attractiveness Analysis

7. Europe Monoclonal Antibodies Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis By Market, 2019-2023
- 7.2.1. By Country
- 7.2.2. By Source Type
- 7.2.3. By Production Type
- 7.2.4. By Application
- 7.2.5. By End User
7.3. Current Market Size (US$ Mn) Analysis and Forecast By Country, 2024-2031
- 7.3.1. Germany
- 7.3.2. France
- 7.3.3. U.K.
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Russia
- 7.3.7. Turkiye
- 7.3.8. Rest of Europe
7.4. Current Market Size (US$ Mn) Analysis and Forecast By Source Type, 2024-2031
- 7.4.1. Human
- 7.4.2. Murine
- 7.4.3. Chimeric
- 7.4.4. Humanized
7.5. Current Market Size (US$ Mn) Analysis and Forecast By Production Type, 2024-2031
- 7.5.1. In Vivo
- 7.5.2. In Vitro
7.6. Current Market Size (US$ Mn) Analysis and Forecast By Application, 2024-2031
- 7.6.1. Infectious Diseases
- 7.6.2. Neurological Diseases
- 7.6.3. Autoimmune Diseases
- 7.6.4. Oncology
- 7.6.5. Others
7.7. Current Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2031
- 7.7.1. Hospitals
- 7.7.2. Specialty Centers
- 7.7.3. Academical and Research Institutes
- 7.7.4. Biopharma Companies
- 7.7.5. Others
7.8. Market Attractiveness Analysis

8. East Asia Monoclonal Antibodies Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis By Market, 2019-2023
- 8.2.1. By Country
- 8.2.2. By Source Type
- 8.2.3. By Production Type
- 8.2.4. By Application
- 8.2.5. By End User
8.3. Current Market Size (US$ Mn) Analysis and Forecast By Country, 2024-2031
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
8.4. Current Market Size (US$ Mn) Analysis and Forecast By Source Type, 2024-2031
- 8.4.1. Human
- 8.4.2. Murine
- 8.4.3. Chimeric
- 8.4.4. Humanized
8.5. Current Market Size (US$ Mn) Analysis and Forecast By Production Type, 2024-2031
- 8.5.1. In Vivo
- 8.5.2. In Vitro
8.6. Current Market Size (US$ Mn) Analysis and Forecast By Application, 2024-2031
- 8.6.1. Infectious Diseases
- 8.6.2. Neurological Diseases
- 8.6.3. Autoimmune Diseases
- 8.6.4. Oncology
- 8.6.5. Others
8.7. Current Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2031
- 8.7.1. Hospitals
- 8.7.2. Specialty Centers
- 8.7.3. Academical and Research Institutes
- 8.7.4. Biopharma Companies
- 8.7.5. Others
8.8. Market Attractiveness Analysis

9. South Asia & Oceania Monoclonal Antibodies Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis By Market, 2019-2023
- 9.2.1. By Country
- 9.2.2. By Source Type
- 9.2.3. By Production Type
- 9.2.4. By Application
- 9.2.5. By End User
9.3. Current Market Size (US$ Mn) Analysis and Forecast By Country, 2024-2031
- 9.3.1. India
- 9.3.2. Southeast Asia
- 9.3.3. ANZ
- 9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Mn) Analysis and Forecast By Source Type, 2024-2031
- 9.4.1. Human
- 9.4.2. Murine
- 9.4.3. Chimeric
- 9.4.4. Humanized
9.5. Current Market Size (US$ Mn) Analysis and Forecast By Production Type, 2024-2031
- 9.5.1. In Vivo
- 9.5.2. In Vitro
9.6. Current Market Size (US$ Mn) Analysis and Forecast By Application, 2024-2031
- 9.6.1. Infectious Diseases
- 9.6.2. Neurological Diseases
- 9.6.3. Autoimmune Diseases
- 9.6.4. Oncology
- 9.6.5. Others
9.7. Current Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2031
- 9.7.1. Hospitals
- 9.7.2. Specialty Centers
- 9.7.3. Academical and Research Institutes
- 9.7.4. Biopharma Companies
- 9.7.5. Others
9.8. Market Attractiveness Analysis

10. Latin America Monoclonal Antibodies Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis By Market, 2019-2023
- 10.2.1. By Country
- 10.2.2. By Source Type
- 10.2.3. By Production Type
- 10.2.4. By Application
- 10.2.5. By End User
10.3. Current Market Size (US$ Mn) Analysis and Forecast By Country, 2024-2031
- 10.3.1. Brazil
- 10.3.2. Mexico
- 10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Mn) Analysis and Forecast By Source Type, 2024-2031
- 10.4.1. Human
- 10.4.2. Murine
- 10.4.3. Chimeric
- 10.4.4. Humanized
10.5. Current Market Size (US$ Mn) Analysis and Forecast By Production Type, 2024-2031
- 10.5.1. In Vivo
- 10.5.2. In Vitro
10.6. Current Market Size (US$ Mn) Analysis and Forecast By Application, 2024-2031
- 10.6.1. Infectious Diseases
- 10.6.2. Neurological Diseases
- 10.6.3. Autoimmune Diseases
- 10.6.4. Oncology
- 10.6.5. Others
10.7. Current Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2031
- 10.7.1. Hospitals
- 10.7.2. Specialty Centers
- 10.7.3. Academical and Research Institutes
- 10.7.4. Biopharma Companies
- 10.7.5. Others
10.8. Market Attractiveness Analysis

11. Middle East & Africa Monoclonal Antibodies Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis By Market, 2019-2023
- 11.2.1. By Country
- 11.2.2. By Source Type
- 11.2.3. By Production Type
- 11.2.4. By Application
- 11.2.5. By End User
11.3. Current Market Size (US$ Mn) Analysis and Forecast By Country, 2024-2031
- 11.3.1. GCC
- 11.3.2. Egypt
- 11.3.3. South Africa
- 11.3.4. Northern Africa
- 11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Mn) Analysis and Forecast By Source Type, 2024-2031
- 11.4.1. Human
- 11.4.2. Murine
- 11.4.3. Chimeric
- 11.4.4. Humanized
11.5. Current Market Size (US$ Mn) Analysis and Forecast By Production Type, 2024-2031
- 11.5.1. In Vivo
- 11.5.2. In Vitro
11.6. Current Market Size (US$ Mn) Analysis and Forecast By Application, 2024-2031
- 11.6.1. Infectious Diseases
- 11.6.2. Neurological Diseases
- 11.6.3. Autoimmune Diseases
- 11.6.4. Oncology
- 11.6.5. Others
11.7. Current Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2031
- 11.7.1. Hospitals
- 11.7.2. Specialty Centers
- 11.7.3. Academical and Research Institutes
- 11.7.4. Biopharma Companies
- 11.7.5. Others
11.8. Market Attractiveness Analysis

12. Competition Landscape

12.1. Market Share Analysis, 2024
12.2. Market Structure
- 12.2.1. Competition Intensity Mapping By Market
- 12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. F. Hoffmann-La Roche Ltd
  - 12.3.1.1. Overview
  - 12.3.1.2. Segments and Products
  - 12.3.1.3. Key Financials
  - 12.3.1.4. Market Developments
  - 12.3.1.5. Market Strategy
- 12.3.2. Novartis AG
- 12.3.3. Pfizer Inc
- 12.3.4. GlaxoSmithKline plc
- 12.3.5. Merck & Co., Inc.
- 12.3.6. Amgen Inc.
- 12.3.7. Daiichi Sankyo Company, Limited
- 12.3.8. Abbott Laboratories
- 12.3.9. AstraZeneca plc
- 12.3.10. Johnson & Johnson Services, Inc.
- 12.3.11. Bayer AG
- 12.3.12. Bristol Myers Squibb
- 12.3.13. F. Hoffman-La Roche Ltd.
- 12.3.14. Biogen Inc.
- 12.3.15. Thermo Fisher Scientific, Inc.
- 12.3.16. Novo Nordisk A/S
- 12.3.17. Sanofi S.A.
- 12.3.18. Lonza
- 12.3.19. ose-immuno
- 12.3.20. AbbVie Inc.
- 12.3.21. UCB S.A.

13. Appendix

13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations